2024年欧洲肿瘤内科学会（ESMO）年会将于09月13日-17日在西班牙巴塞罗那盛大启幕。近日，ESMO官方网站已公布了LBA（Late-Breaking Abstract）的摘要标题。其中，复旦大学附属肿瘤医院胡夕春教授，作为DESTINY-Breast06研究的主要研究者之一，将展示该研究的患者报告结局。本期【肿瘤资讯】整理了乳腺癌领域的LBA研究标题，以期为读者带来最前沿的学术资讯。
主席研讨会Ⅱ——改变实践的试验
Presidential Symposium II: Practice-changing trials
专场时间：2024年09月15日16:30 - 18:05（本文时间均为西班牙时间，比北京时间晚6个小时）
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA4
新辅助帕博利珠单抗/安慰剂联合化疗后帕博利珠单抗或安慰剂辅助治疗高危早期TNBC：Ⅲ期KEYNOTE-522研究的总生存期结果
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study
讲者：Peter Schmid (London, United Kingdom)
优选论文专场——早期乳腺癌
Proffered Paper session - Breast cancer, early stage
专场时间：2024年09月16日10:15 - 11:45
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA10
Ⅱ期Neo-CheckRay试验：立体定向放疗±度伐利尤单抗±oleclumab联合新辅助化疗治疗早期高危ER+/HER2-乳腺癌的主要结局
Primary endpoint results of the Neo-CheckRay phase II trial evaluating stereotactic body radiation therapy (SBRT) +/- durvalumab (durva) +/- oleclumab (ole) combined with neo-adjuvant chemotherapy (NACT) for early-stage, high risk ER+/HER2- breast cancer (BC).
讲者：Alex De Caluwe (Brussels, Belgium)
摘要号：LBA11
新辅助纳武利尤单抗/relatlimab或纳武利尤单抗/伊匹木单抗治疗高肿瘤浸润淋巴细胞（TIL）的三阴性乳腺癌
Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)
讲者：Iris Nederlof (Amsterdam, Netherlands)
摘要号：LBA12
eMouvoir：评估个性化和远程身体活动对乳腺癌幸存者影响的随机III期试验的生活质量结果
eMouvoir: Randomised phase 3 trial evaluating the impact of a personalized and remote Physical Activity (PA) for Breast Cancer Survivors (BCS). Results on the Quality of Life (QoL).
讲者：Laurence Vanlemmens (Lille, France, CEDEX)
摘要号：LBA13
瑞波西利联合非甾体芳香化酶抑制剂（NSAI）辅助治疗HR+/HER2-的早期乳腺癌（EBC）患者：NATALEE试验的4年结局
Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients (Pts) With HR+/HER2− Early Breast Cancer (EBC): 4-Year Outcomes From the NATALEE Trial
讲者：Peter A. Fasching (Erlangen, Germany)
简短口头报告专场——早期乳腺癌
Mini oral session - Breast cancer, early stage
专场时间：2024年09月14日10:15-11:45
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA14
随机对照SAPITO试验：强化烷化剂化疗联合自体干细胞移植（IACT）或常规化疗后序贯奥拉帕利（CCT-O）治疗Ⅲ期、HER2阴性、同源重组缺陷(HRD)乳腺癌的生存结果
Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
讲者：Sabine Linn (Amsterdam, Netherlands)
摘要号：LBA15
Datopotamab Deruxtecan（Dato-Dxd）联合度伐利尤单抗治疗方案在新辅助环境中的病理完全缓解率（pCR）：I-SPY 2.2试验结果
Rates of Pathologic Complete Response (pCR) after Datopotamab Deruxtecan (Dato) plus Durvalumab (Durva) Treatment Strategy in the Neoadjuvant Setting: Results from the I-SPY 2.2 Trial
讲者：Meghna S. Trivedi (New York, United States of America)
摘要号：LBA16
Dato-Dxd在新辅助环境中的pCR：I-SPY 2.2试验结果
Rates of Pathologic Complete Response (pCR) after Datopotamab Deruxtecan (Dato) in the Neoadjuvant setting: Results from the I-SPY 2.2 Trial
讲者：Katia Khoury (Birmingham, United States of America
摘要号：LBA17
WSG-TP-Ⅱ试验：新辅助内分泌治疗联合曲妥珠单抗和帕妥珠单抗（ET+T+P）对比降级化疗（CT）+T+P在HR+/HER2+ EBC中的生存结果
Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
讲者：Oleg Gluz (Mönchengladbach, Germany)
优选论文专场——转移性乳腺癌
Proffered Paper session - Breast cancer, metastatic
专场时间：2024年09月13日16:00 - 17:30
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA18
DESTINYBreast-12研究：德曲妥珠单抗（T-DXd）治疗伴或不伴脑转移（BM）的HER2+晚期转移性乳腺癌患者的初步结果
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
讲者：Nancy Lin (Boston, United States of America)
摘要号：LBA19
Ⅲ期CAPItello-290 试验：Capivasertib+紫杉醇一线治疗转移性三阴性乳腺癌（mTNBC）
Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): the CAPItello-290 Phase 3 trial
讲者：Peter Schmid (London, United Kingdom)
摘要号：LBA20
一线卡铂+环磷酰胺对比紫杉醇±阿替利珠单抗治疗mTNBC：多中心、随机Ⅱb期Triple-B试验结果（BOOG 2013-01）
First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: the Triple-B study (BOOG 2013-01)
讲者：Marleen Kok (Amsterdam, Netherlands)
简短口头报告专场1——转移性乳腺癌
Mini oral session 1 - Breast cancer, metastatic
专场时间：2024年09月15日08:00-10:00
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA21
DESTINY-Breast06（DB-06）研究中HR+转移性乳腺癌（mBC）的HER2低表达和HER2超低表达测定
Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)
讲者：Giuseppe Viale (Milan, Italy)
摘要号：LBA22
DB-06研究： T-DXd vs 选择性化疗（TPC ）对HR阳性/HER2低表达或超低表达mBC患者报告结局（PRO）的影响
Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): results from DESTINY-Breast06
讲者：胡夕春 (中国, 上海)
简短口头报告专场2——转移性乳腺癌
Mini oral session 2 - Breast cancer, metastatic
专场时间：2024年09月16日08:30-10:00
专场地点：Barcelona Auditorium - Hall 2
摘要号：LBA23
随机Ⅱ期ABIGAIL研究：阿贝西利+ET联合或不联合紫杉醇短期诱导治疗具有侵袭性疾病特征的初治HR+/HER2-晚期乳腺癌患者
ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
讲者：Juan De la Haba Rodriguez (Cordoba, Spain)
简短口头报告专场——政策和预防策略
Mini oral session - Policy and preventive strategies
专场时间：2024年09月16日14:45-16:15
专场地点：Zaragoza Auditorium - CC5
摘要号：LBA64
卵巢癌和乳腺癌患者的BRCA和内部HRD检测结果：一项多中心注册研究
Outcomes of BRCA and in-house homologous recombination deficiency (HRD) testing in women with ovarian and breast cancer; A multicentre registry study
讲者：Kyrillus S. Shohdy (Giza, Egypt)
https://cslide.ctimeetingtech.com/esmo2024/attendee/confcal/session
排版编辑：肿瘤资讯-张薪媛
苏公网安备32059002004080号
